Clinical trials: Drug Drug Interaction (DDI)
Drug Interaction Potentiation
Pharmacokinetic Interaction Study of Dapoxetine 30mg and Mirodenafil 100mg
Healthy male volunteers were administered alone and in combination with dapoxetine 30mg mirodenafil 100mg for three times, respectively and the pharmacokinetic interaction was compared between the two drugs.
- Trial name
- NCT02485041
- Testing
- Dapoxetine 30mg, Mirodenafil 100mg
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- SK Chemicals Co., Ltd.
Gout Chronic, Gout
Drug-Drug Interaction Study of ABP-671 in Gout Patients
This is a open-Label, Within-Subject Drug-Drug Interaction Study of ABP-671 Added to Stable Allopurinol Therapy in Gout Patients.
- Conditions
- Gout Chronic, Gout, DDI (Drug-Drug Interaction)
- Trial name
- NCT07367971
- Testing
- ABP-671 plus allopurinol
- Where
- United States
- Volunteers
- 22 people
- Sponsor
- Atom Therapeutics Co., Ltd
Trypanosomiasis, African
DDI Study of Single Oral Dose of Acoziborole With Sequential Co-administration of Midazolam and Dextromethorphan
To assess Drug drug interactions between Acoziborole and Dextromethorphan and Midazolam in healthy male volunteers.
- Trial name
- OXA-07 (NCT05947604)
- Testing
- Acoziborole, Midazolam, Dextromethorphan
- Where
- Malaysia
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Drugs for Neglected Diseases
Healthy Volunteer
Study to Assess the Safety, Tolerability, PK, ECG Effects, Food Effect, and Drug-drug Interaction (DDI) of Hormonal Contraceptives of PTI-428 in Healthy Female Volunteers
This trial will consist of three parts: the first two parts will enroll healthy female volunteers into a single ascending dose (SAD) and multiple ascending dose (MAD) treatment groups.
- Trial name
- NCT02846142
- Testing
- PTI-428, ethinyl estradiol and levonorgestrel
- Where
- United States
- Volunteers
- 94 people, healthy volunteers welcome
- Sponsor
- Proteostasis Therapeutics, Inc.
HIV Infections
DDI HV (ATV - Merck)
The purpose of this study is to to assess the effect of ATV 300 mg BID on the PK of raltegravir 400 mg BID, to assess the effect of raltegravir 400 mg BID on the PK of ATV 300 mg BID, and to assess the ECG effects of ATV 300 mg…
- Trial name
- NCT00518297
- Testing
- Raltegravir, Atazanavir, Atazanavir + Raltegravir
- Where
- United States
- Volunteers
- 22 people, healthy volunteers welcome
- Sponsor
- Bristol-Myers Squibb
Healthy
A Drug Drug Interaction (DDI) Study of Pirtobrutinib (LY3527727) and Rosuvastatin in Healthy Participants
The main purpose of this study is to determine the effect of pirtobrutinib on the levels of rosuvastatin in the blood stream in healthy participants.
- Trial name
- NCT05176314
- Testing
- Rosuvastatin, Pirtobrutinib
- Where
- 2 sites in United States
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- Loxo Oncology, Inc.
cMET-dysregulated Advanced Solid Tumors
A DDI Study to Assess the Effect of INC280 on the PK of Midazolam and Caffeine in Patients With cMET-dysregulated Advanced Solid Tumors
Drg-drug Interaction (DDI) study to assess the effect of INC280 on the pharmacokinetics of midazolam and caffeine in patients with cMET-dysregulated advanced solid tumors
- Trial name
- NCT02520752
- Testing
- INC280, Midazolam, Caffeine
- Where
- 12 sites in United States, Bulgaria and 5 more
- Volunteers
- 37 people
- Sponsor
- Novartis Pharmaceuticals
Obesity
A Drug-Drug Interaction (DDI) Study of LY3437943 in Obese Participants
The main purpose of this study is to determine the effect of LY3437943 when administered subcutaneously on the levels of midazolam, warfarin and caffeine in the blood stream when administered orally as a drug cocktail in obese…
- Trial name
- NCT05445232
- Testing
- LY3437943, Midazolam, Warfarin
- Where
- 2 sites in United States
- Volunteers
- 32 people
- Sponsor
- Eli Lilly and Company
Pharmacokinetics
Drug-Drug Interaction (DDI) Study of Leramistat in Healthy Adult Subjects
A DDI study consisting of 4 parts conducted as an open label, fixed sequence study in healthy adult subjects.
- Trial name
- NCT06379958
- Testing
- leramistat 40mg, Itraconazole 200 mg, Phenytoin 100 Mg Oral Capsule
- Where
- United Kingdom
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- Modern Biosciences Ltd
Gout, Hyperuricemia
Open Label PK, PD and DDI of Dotinurad and Allopurinol in Gout Patients With Hyperuricemia
A open label multi-center 3-period multidose, PK/PD and drug-drug interaction (DDI) study to evaluate the pharmacokinetics (PK) and pharmacodynamics (PD) of 7 days of treatment with two doses of dotinurad monotherapy, and to…
- Trial name
- NCT06056570
- Testing
- dotinurad, dotinurad + allopurinol, allopurinol
- Where
- 4 sites in United States
- Volunteers
- 20 people
- Sponsor
- Urica Therapeutics Inc.
Anesthesia, Sedation
A Study Evaluating Drug-Drug Interaction (DDI) Between HSK3486 Injectable Emulsion and Voriconazole Tablets
This is a single-center, open-label, randomized, two-stage, two-way crossover study evaluating the effect of voriconazole on the PK, PD, and safety of HSK3486 in healthy subjects.
- Trial name
- NCT04145583
- Testing
- HSK3486, voriconazole +HSK3486
- Where
- China
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- Sichuan Haisco Pharmaceutical Group Co., Ltd
Tuberculosis
A Study to Investigate the Repeat-dose Pharmacokinetics of a Combined Oral Contraceptive When Given Alone and in Combination With Ganfeborole in Female Participants of Non-childbearing Potential
This study is designed to assess the pharmacokinetics (PK), safety, and tolerability of Ganfeborole and Microgynon, an oral contraceptive containing ethinylestradiol (EE) and levonorgestrel (LNG), when Microgynon is administered…
- Trial name
- NCT07784894
- Testing
- Ganfeborole, Microgynon
- Where
- Spain
- Volunteers
- 28 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Drug Interaction
DDI Study to Investigate the Impact of Itraconazole on the Pharmacokinetics of Dorzagliatin
The purpose of this study is to investigate the impact of itraconzaole on the pharmacokinetics of Dorzagliatin.
- Trial name
- NCT04080596
- Testing
- Dorzagliatin
- Where
- China
- Volunteers
- 18 people
- Sponsor
- Hua Medicine Limited
Atopic Dermatitis
Open Label, Drug-Drug Interaction (DDI) Study of Dupilumab (REGN668/SAR231893) in Patients With Moderate to Severe Atopic Dermatitis (AD)
This is an open-label, single-sequence DDI study designed to examine the effects of dupilumab on the pharmacokinetics of selected cytochrome P450 substrates in adult patients with moderate to severe AD.
- Trial name
- NCT02647086
- Testing
- Dupilumab, Midazolam, Omeprazole
- Where
- 5 sites in United States
- Volunteers
- 14 people
- Sponsor
- Regeneron Pharmaceuticals
Chronic Hepatitis B Liver Fibrosis, DDI (Drug-Drug Interaction)
Drug-Drug Interaction Study Between Hydronidone and Entecavir, Tenofovir Disoproxil Fumarate, Tenofovir Alafenamide, and Tenofovir Amibufenamide
The proposed indication for Hydronidone Capsules is chronic hepatitis B-associated liver fibrosis, which in clinical practice typically requires concomitant use with antiviral agents for chronic hepatitis B.
- Trial name
- NCT07295873
- Testing
- Entecavir, Tenofovir Disoproxil Fumarate（TDF）, Tenofovir alafenamide（TAF）
- Where
- China
- Volunteers
- 64 people, healthy volunteers welcome
- Sponsor
- Beijing Continent Pharmaceutical Co, Ltd.
Malaria
Drug-drug Interaction Study of Ganaplacide and Lumefantrine With Efavirenz
This study assessed the effect of multiple doses of a moderate inducer of cytochrome P450 (CYP) 3A4 (efavirenz) on the pharmacokinetics (PK) of ganaplacide and lumefantrine combination.
- Trial name
- NCT05330273
- Testing
- Ganaplacide, Lumefantrine, Efavirenz
- Where
- United Kingdom
- Volunteers
- 14 people, healthy volunteers welcome
- Sponsor
- Novartis Pharmaceuticals
Drug Interaction Potential
Effect of Pexidartinib on the Way the Body Processes CYP3A4 and CYP2C9 Substrates (Pharmacokinetics)
This study has two parts. Part 1 will evaluate how pexidartinib affects the way the body processes CYP3A4 and CYP2C9 substrates using midazolam and tolbutamide, respectively, as probe agents.
- Trial name
- NCT03291288
- Testing
- Tolbutamide, Midazolam, Pexidartinib
- Where
- 11 sites in United States, Netherlands and 2 more
- Volunteers
- 32 people
- Sponsor
- Daiichi Sankyo
Drug Drug Interaction (DDI)
A Study Evaluating the Potential of BMS-984923 to Alter the Systemic Exposure of Three Orally Administered Probe Substrates
The goal of this study is to learn if the investigational drug, BMS-984923 will impact the exposure and clearance of other medications when given together.
- Trial name
- NCT06632990
- Testing
- BMS-984923, Midazolam, Caffeine
- Where
- United States
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- Allyx Therapeutics
Healthy Participants
A Drug-drug Interaction Study to Assess the Effect of Phenytoin and Itraconazole on the Pharmacokinetics of Pelabresib in Healthy Participants
The purpose of this study is to assess the effect of multiple doses of phenytoin, a strong cytochrome P450 (CYP)3A4 inducer, and itraconazole, a strong CYP3A4 inhibitor, on the pharmacokinetic (PK) profile of DAK539 (hereafter…
- Trial name
- NCT07783503
- Testing
- Pelabresib, Phenytoin, Itraconazole
- Where
- United Kingdom
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Novartis Pharmaceuticals
Solid Tumor
IMP4297 DDI (Drug-Drug Interaction)Trial in Healthy Male Volunteers
A Phase I, Open-label, Fixed-Sequence Study to Evaluate the Effect of Multiple-dose Itraconazole or Rifampicin Capsules on the Single-dose PK Profiles of IMP4297 Capsules in Healthy Subjects
- Trial name
- NCT04584515
- Testing
- IMP4297 40 mg, IMP4297 100 mg
- Where
- China
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- Impact Therapeutics, Inc.